Products and
Pipeline

Overview¹

TAK-252 is an agonist redirected checkpoint fusion protein that may lead to T cell activation by converting a checkpoint inhibitor engager into a T cell stimulator ligand and thus allowing for a T-cell mediated anti-tumor response

MOA¹

TAK-252 is a two-sided human fusion protein incorporating the extracellular domains of PD-1 and OX40L, adjoined by a central Fc domain (PD1-Fc-OX40L):

- The PD-1 end of the fusion protein binds and blocks PD-L1 and PD-L2

- The OX40L end binds OX40 and translates to potent stimulation of OX40 signaling

Clinical Trials

Study Name

Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas

Reference

1. Fromm G, et al. J Immunother Cancer. 2018;6:149.

Disclaimers

*Takeda retains an option to develop TAK-252 / SL-279252 with Shattuck Labs.